Supplemental material for JAAD publication titled: A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results"

Supplemental material for JAAD publication titled: "A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results" to be published in Journal of the American Academy of Dermatology

本材料为即将发表于《美国皮肤病学会杂志（Journal of the American Academy of Dermatology, JAAD）》、标题为《司库奇尤单抗治疗中重度斑块状银屑病儿科患者的III期开放标签多中心随机研究：24周疗效结果》的学术论文的补充资料。